Abeona Therapeutics Inc.
Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
– Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 –
Company newsroom
Abeona Therapeutics Inc.
NASDAQ:ABEO
1 releases